Covex S.A. creates 2000 jobs with the onset of a new agroindustrial project in Latin America

Covex S.A.Covex S.A., leader in the manufacture of products aimed at improving cerebral functions, successfully reaches the first stage of its introduction in Latin America, as it begins to harvest medicinal plants on an industrial scale, for the onset of its new agroindustrial expansion.

At the same time, Covex will transfer its patented technologies for the obtention of the pharmaceutical active ingredients. Dr. Fernando Calvo, President of Covex S.A., states: "This project will reap benefits, not only in terms of greater manufacturing competitiveness, but also in the form of social consequences in those countries where it is to be introduced."

Maria Eugenia Lima, President of Fundación Mujer y Familia Andina, Ecuadorian Farm workers Cooperative Organization associated with Covex, declares that the agricultural development reached has been a success, with highly satisfactory yields, thanks to the highly capable farm workers in Ecuador, alleviating the damaged profitability of the Ecuadorian coffee growers.

On his part, Fernando Posada, President of Extracciones Naturales S.A. de C.V. Mexico, another industrial partner of Covex, comments: "We are very satisfied about playing an integral part in this project, as our vast experience and the excellent quality of our facilities makes our company ideal for successfully receiving and introducing this technological transfer from Spain."

About Covex S.A.
Since 1977 Covex has specialized in R+D+i, production, and commercialization of nutraceutical and pharmaceutical products aimed at improving brain functions, (memory, attention, etc.). These include the drug Vinpocetine Covex 5mg, and the nutraceuticals: Intelectol® or its award winning "Memory drinks" such as Memocafe® or Memotea®, Memocola®, etc.

After a quarter of a century of R+D+i, leading the way in the production of goods derived from the Vinca family in the world, Covex has been exporting since 1980, more than 95% of its production to 60 countries, and currently has subsidiaries abroad.

The business activity is based on price competitiveness and high quality, and on the immediate delivery of its products around the globe. The company presently possesses over 200 patents and trademarks in more than 100 countries.

For more information, visit www.covex.com.

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Disparities in United States COVID-19 vaccine dist…

When reports showed COVID-19 vaccination rates were lower among racial/ethnic minority groups, most discussions focused on mistrust and misinformation among these populat...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

GSK signs agreement to support pandemic preparedne…

GSK plc (LSE/NYSE: GSK) announced it had signed a framework contract with the European Commission's (EC) Health Emergency Preparedness and Response Authority (HERA) for t...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...